Highview Capital Management LLC DE Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Highview Capital Management LLC DE increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,079 shares of the pharmaceutical company’s stock after buying an additional 121 shares during the period. Vertex Pharmaceuticals accounts for approximately 1.1% of Highview Capital Management LLC DE’s portfolio, making the stock its 23rd largest holding. Highview Capital Management LLC DE’s holdings in Vertex Pharmaceuticals were worth $2,067,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC raised its position in Vertex Pharmaceuticals by 1.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after purchasing an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC raised its position in Vertex Pharmaceuticals by 3.2% during the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after purchasing an additional 25 shares in the last quarter. Cooper Financial Group raised its position in Vertex Pharmaceuticals by 1.0% during the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock valued at $1,050,000 after purchasing an additional 29 shares in the last quarter. Arjuna Capital raised its position in Vertex Pharmaceuticals by 0.7% during the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after purchasing an additional 29 shares in the last quarter. Finally, FRG Family Wealth Advisors LLC raised its position in Vertex Pharmaceuticals by 0.9% during the third quarter. FRG Family Wealth Advisors LLC now owns 3,292 shares of the pharmaceutical company’s stock valued at $1,145,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,381 shares of company stock worth $5,203,249. Insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on VRTX shares. Royal Bank of Canada raised their price target on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 6th. Wolfe Research began coverage on Vertex Pharmaceuticals in a report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. Robert W. Baird downgraded Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective on the stock. in a report on Wednesday, January 31st. Barclays lifted their price objective on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $420.33.

Read Our Latest Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Down 0.9 %

Vertex Pharmaceuticals stock traded down $3.68 during trading hours on Friday, hitting $396.55. 1,187,932 shares of the stock traded hands, compared to its average volume of 1,260,359. The firm’s 50-day moving average price is $416.91 and its two-hundred day moving average price is $395.19. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The company has a market cap of $102.49 billion, a PE ratio of 28.66, a PEG ratio of 2.16 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a one year low of $316.43 and a one year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the firm posted $3.33 EPS. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.